Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 17, Issue 2, 2017, Pages 184-193

  Gutman, Julie ^a   Kovacs, Stephanie ^b   Dorsey, Grant ^c   Stergachis, Andy ^b   ter Kuile, Feiko O ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PIPERAQUINE; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ALLERGIC REACTION; ARTICLE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXPOSURE; GROUPS BY AGE; HUMAN; INCIDENCE; INFECTION PREVENTION; MALARIA; META ANALYSIS; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REPEATED DRUG DOSE; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; VOMITING; COMBINATION DRUG THERAPY; DRUG COMBINATION;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; PYRIMETHAMINE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFADOXINE;

EID: 85006826697     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30378-4     Document Type: Article

References (39)

1. 1 Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. 2 Desai, M, ter Kuile, FO, Nosten, F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7 (2007), 93–104.
3. 3 World Health Organization. World Malaria Report 2015, 2015, WHO Press, Geneva, Switzerland.
4. 4 World Health Organization. Guidelines for the treatment of malaria, 3rd edn., 2015, World Health Organization, Geneva, Switzwerland.
5. 5 Smithuis, F, Kyaw, MK, Phe, O, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367 (2006), 2075–2085.
6. 6 Zongo, I, Milligan, P, Compaore, YD, et al. Randomized non-inferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for SMC in Burkina Faso. Antimicrob Agents Chemother 59 (2015), 4387–4396.
7. 7 Pekyi, D, Ampromfi, AA, Tinto, H, et al. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med 374 (2016), 913–927.
8. 8 Makanga, M, Krudsood, S, The clinical efficacy of artemether/lumefantrine (Coartem). Malar J, 8(suppl 1), 2009, S5.
9. 9 Sinclair, D, Zani, B, Donegan, S, Olliaro, P, Garner, P, Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev, 3, 2009 CD007483.
10. 10 Dzinjalamala, FK, Macheso, A, Kublin, JG, et al. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother 49 (2005), 3601–3606.
11. 11 Sinclair, D, Donegan, S, Isba, R, Lalloo, DG, Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev, 6, 2012 CD005967.
12. 12 Myint, HY, Ashley, EA, Day, NP, Nosten, F, White, NJ, Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 101 (2007), 858–866.
13. 13 Agency, EM, Eurartesim. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001199/human_med_001450.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true, 2013 (accessed May 16, 2015).
14. 14 Schwartz, PJ, Stramba-Badiale, M, Crotti, L, et al. Prevalence of the congenital long-QT syndrome. Circulation 120 (2009), 1761–1767.
15. 15 Owens, RC Jr, Nolin, TD, Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 43 (2006), 1603–1611.
16. 16 Lopez, JA, Harold, JG, Rosenthal, MC, Oseran, DS, Schapira, JN, Peter, T, QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 59 (1987), 376–377.
17. 17 Traebert, M, Dumotier, B, Antimalarial drugs: QT prolongation and cardiac arrhythmias. Expert opinion on drug safety 4 (2005), 421–431.
18. 18 Darpo, B, Nebout, T, Sager, PT, Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline. J Clin Pharmacol 46 (2006), 498–507.
19. 19 Manning, J, Vanachayangkul, V, Lon, C, et al. Randomized double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT tnterval. Antimicrob Agents Chemother 58 (2014), 6056–6067.
20. 20 Wanzira, H, Kakuru, A, Arinaitwe, E, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis 59 (2014), 509–516.
21. 21 Pharmaceuticals, S-T, Eurartemis: Summary of Product Characteristics [Brochure]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf, 2011 (accessed Feb 16, 2016).
22. 22 Adjei, A, Narh-Bana, S, Amu, A, et al. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malaria J 15 (2016), 1–10.
23. 23 Borsini, F, Crumb, W, Pace, S, et al. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother 56 (2012), 3261–3270.
24. 24 Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
25. 25 Higgins, J, Green, S, The Cochrane handbook for systematic reviews of interventions, 2006, John Wiley & Sons, Chichester, UK.
26. 26 Wells, G, Shae, B, O'Connell, D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/nos_manual.pdf, 2014 (accessed May 26, 2015).
27. 28 Tagbor, H, Antwi, GD, Acheampong, PR, Bart Plange, C, Chandramohan, D, Cairns, M, Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. Trop Med Int Health 21 (2016), 224–235.
28. 29 Rijken, MJ, McGready, R, Boel, ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg 78 (2008), 543–545.
29. 30 Poespoprodjo, JR, Fobia, W, Kenangalem, E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One, 9, 2014, e84976.
30. 31 Bigira, V, Kapisi, J, Clark, TD, et al. Protective Efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med, 11, 2014, e1001689.
31. 32 Bojang, K, Akor, F, Bittaye, O, et al. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One, 5, 2010, e11225.
32. 33 Cisse, B, Cairns, M, Faye, E, et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One, 4, 2009, e7164.
33. 34 Kamya, MR, Kapisi, J, Bigira, V, et al. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS 28 (2014), 2701–2709.
34. 35 Nankabirwa, JI, Wandera, B, Amuge, P, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 58 (2014), 1404–1412.
35. 36 Lwin, KM, Phyo, AP, Tarning, J, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56 (2012), 1571–1577.
36. 37 Desai, M, Gutman, J, L'Lanziva, A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet 386 (2015), 2507–2519.
37. 38 Kakuru, A, Jagannathan, P, Muhindo, M, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. New Engl J Med 374 (2016), 928–939.
38. 39 Zani, B, Gathu, M, Donegan, S, Olliaro, PL, Sinclair, D, Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev, 1, 2014 CD010927.
39. 27 Sweeting, M, Sutton, AJ, Lambert, PC, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004), 1351–1375.